OR WAIT null SECS
© 2022 MJH Life Sciences and Pharmaceutical Executive. All rights reserved.
© 2022 MJH Life Sciences™ and Pharmaceutical Executive. All rights reserved.
Some observations point to hope for an upturn.
Living to fight another day, as potential investment spark looms.
What will current stranglehold mean for industry down the line?
But a doubling-down on R&D offers reason for optimism.
Biopharma stock performance continues to struggle.
Brief summary of EY’s 2022 M&A Firepower report highlights trends.